CTOs on the Move

BioAge Labs

www.bioagelabs.com

 
BIOAGE has a diverse team of computational biologists and medical scientists with expertise in aging and translational research. We share the vision that a synergy of machine learning approaches, high throughput human omics data, and new experimental approaches will make it possible to discover therapies that address unmet medical needs in an aging population.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

BioAge Labs raised $10.9M on 07/28/2017
BioAge Labs raised $23M on 01/24/2019

Similar Companies

Zija International

Zija International is a Lindon, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cerus

Cerus Corporation is dedicated solely to safeguarding the world`s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.

Strategic Partnerships

Strategic Partnerships, LLC is a Alexandria, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Evelo Therapeutics

Evelo Therapeutics is the latest breakthrough microbiome company from Flagship VentureLabs, the innovation foundry of Flagship Ventures.

Avrobio

AVROBIO`s vision is to bring personalized gene therapy to the world. We aim to prevent, halt or reverse disease throughout the body with a single dose of gene therapy designed to drive durable expression of therapeutic protein, even in hard-to-reach tissues and organs including brain, muscle and bone. Our ex vivo lentiviral gene therapy pipeline includes clinical programs in Fabry disease, Gaucher disease type 1 and cystinosis, as well as preclinical programs in Hunter syndrome, Gaucher disease type 3 and Pompe disease. AVROBIO is powered by our industry leading plato® gene therapy platform, our foundation designed to deliver gene therapy worldwide. We are headquartered in Cambridge, Mass., with an office in Toronto, Ontario.